4//SEC Filing
GANNON STEVEN 4
Accession 0000950170-25-083321
CIK 0001582313other
Filed
Jun 5, 8:00 PM ET
Accepted
Jun 6, 5:58 PM ET
Size
9.0 KB
Accession
0000950170-25-083321
Insider Transaction Report
Form 4
GANNON STEVEN
Director
Transactions
- Sale
Common Shares
2025-06-05$30.48/sh−3$91→ 7,141 total - Award
Share Option (Right to Buy)
2025-06-05+17,012→ 17,012 totalExercise: $30.73Exp: 2035-06-04→ Common Shares (17,012 underlying) - Award
Restricted Share Units
2025-06-05+2,645→ 2,645 totalExercise: $0.00→ Common Shares (2,645 underlying)
Footnotes (3)
- [F1]Shares automatically sold in payment of transfer fee for transfer of shares to an alternate brokerage account.
- [F2]Vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.
- [F3]Each restricted share unit represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 4, 2026 or (ii) the day before the date of the issuer's 2026 annual meeting of shareholders.
Documents
Issuer
Xenon Pharmaceuticals Inc.
CIK 0001582313
Entity typeother
Related Parties
1- filerCIK 0001643085
Filing Metadata
- Form type
- 4
- Filed
- Jun 5, 8:00 PM ET
- Accepted
- Jun 6, 5:58 PM ET
- Size
- 9.0 KB